Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-rituximab plus panobinostat for relapsed/refractory indolent B-cell lymphoma
ACTRN12612000746831Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat, iodine-131-rituximab and rituximab in mature B-cell lymphoma and low-grade B-cell lymphoma (3 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Incidence of dose-limiting toxicities. Started May 2012; status: recruiting.
02
Drugs
panobinostatiodine-131-rituximabrituximab
03
Conditions
mature B-cell lymphomalow-grade B-cell lymphoma
Beyond the preview
Go deeper on ACTRN12612000746831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000746831.